135 related articles for article (PubMed ID: 7819092)
1. Multiple myeloma: why does the disease escape from plateau phase?
Joshua DE; Brown RD; Gibson J
Br J Haematol; 1994 Dec; 88(4):667-71. PubMed ID: 7819092
[No Abstract] [Full Text] [Related]
2. Mechanisms of the escape phase of myeloma.
Joshua DE; Gibson J; Brown RD
Blood Rev; 1994 Mar; 8(1):13-20. PubMed ID: 8205006
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma: increasing evidence for a multistep transformation process.
Hallek M; Bergsagel PL; Anderson KC
Blood; 1998 Jan; 91(1):3-21. PubMed ID: 9414264
[TBL] [Abstract][Full Text] [Related]
4. [Identification of gene aberrations involved in the pathogenesis of multiple myeloma].
Iida S; Ueda R
Rinsho Ketsueki; 2000 May; 41(5):408-13. PubMed ID: 10879101
[No Abstract] [Full Text] [Related]
5. [Plasma cell myeloma. I. A new concept of disease biology].
Barlogi B; Epstein J; Selvaniagam P; Alexanian R
Gematol Transfuziol; 1991 Aug; 36(8):29-35. PubMed ID: 1752407
[No Abstract] [Full Text] [Related]
6. Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma.
Greipp PR; Lust JA
Stem Cells; 1995 Aug; 13 Suppl 2():10-21. PubMed ID: 8520496
[TBL] [Abstract][Full Text] [Related]
7. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
Gadó K; Domján G; Hegyesi H; Falus A
Cell Biol Int; 2000; 24(4):195-209. PubMed ID: 10816321
[TBL] [Abstract][Full Text] [Related]
8. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype.
Pope B; Brown R; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1997 May; 25(5-6):545-54. PubMed ID: 9250826
[TBL] [Abstract][Full Text] [Related]
9. The oncoprotein phenotype of plasma cells from patients with multiple myeloma.
Brown RD; Pope B; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1994 Dec; 16(1-2):147-56. PubMed ID: 7696921
[TBL] [Abstract][Full Text] [Related]
10. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.
Zhang XG; Gaillard JP; Robillard N; Lu ZY; Gu ZJ; Jourdan M; Boiron JM; Bataille R; Klein B
Blood; 1994 Jun; 83(12):3654-63. PubMed ID: 8204890
[TBL] [Abstract][Full Text] [Related]
11. [Multiple myeloma. Mechanisms of proliferation and neoplastic progression and their clinical implications].
Boccadoro M; Battaglio S; Dianzani U; Frieri R; Gallone G; Massaia M; Omedè P; Palumbo A; Pileri A
Haematologica; 1991 Jun; 76 Suppl 3():100-6. PubMed ID: 1752506
[No Abstract] [Full Text] [Related]
12. Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance.
Zojer N; Schuster-Kolbe J; Assmann I; Ackermann J; Strasser K; Hübl W; Drach J; Ludwig H
Br J Haematol; 2002 Jun; 117(4):852-9. PubMed ID: 12060120
[TBL] [Abstract][Full Text] [Related]
13. The biological features of multiple myeloma.
Michaeli J; Choy CG; Zhang X
Cancer Invest; 1997; 15(1):76-84. PubMed ID: 9028393
[No Abstract] [Full Text] [Related]
14. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.
Klein B; Seckinger A; Moehler T; Hose D
Recent Results Cancer Res; 2011; 183():39-86. PubMed ID: 21509680
[TBL] [Abstract][Full Text] [Related]
15. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
[TBL] [Abstract][Full Text] [Related]
16. Is myeloma really a monoclonal disease?
Durie BG
Br J Haematol; 1984 Jul; 57(3):357-64. PubMed ID: 6743562
[No Abstract] [Full Text] [Related]
17. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF
Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290
[TBL] [Abstract][Full Text] [Related]
18. [Multiple myeloma--the biology of malignant plasma cells].
Paluszewska M
Pol Arch Med Wewn; 1996 Jan; 95(1):67-72. PubMed ID: 8677197
[No Abstract] [Full Text] [Related]
19. Etiology of multiple myeloma: what's new.
Berenson JR
Semin Oncol; 1999 Oct; 26(5 Suppl 13):2-9. PubMed ID: 10528889
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 in human multiple myeloma.
Klein B; Zhang XG; Lu ZY; Bataille R
Blood; 1995 Feb; 85(4):863-72. PubMed ID: 7849308
[No Abstract] [Full Text] [Related]
[Next] [New Search]
